Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...

Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep ...

Recurrent meningitis is a rare but serious condition, occurring in about 5% of cases of community-acquired meningitis.

Red cell alloantibodies are primarily IgG and less often IgM. IgM antibodies readily fix complement and it is these that classically cause the intravascular AHTR. IgG antibodies typically cause ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...

Breastfeeding is important and essential for the child, especially in the first 6 months. Now, a new research further expands ...

Despite the therapeutic benefits of IgM antibodies a major technological drawback has been identified in comparison to the classical IgG molecule. Recombinant production of this immunoglobulin class ...